- Home
- ALLR vs DRMA Comparison
ALLR vs DRMA Comparison
Compare ALLR & DRMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALLR
- DRMA
- Stock Information
- Founded
- ALLR 2004
- DRMA 2014
- Country
- ALLR United States
- DRMA United States
- Employees
- ALLR N/A
- DRMA N/A
- Industry
- ALLR Biotechnology: Pharmaceutical Preparations
- DRMA Biotechnology: Pharmaceutical Preparations
- Sector
- ALLR Health Care
- DRMA Health Care
- Exchange
- ALLR Nasdaq
- DRMA Nasdaq
- Market Cap
- ALLR 4.0M
- DRMA 4.5M
- IPO Year
- ALLR N/A
- DRMA 2021
- Fundamental
- Price
- ALLR $0.87
- DRMA $0.72
- Analyst Decision
- ALLR
- DRMA Strong Buy
- Analyst Count
- ALLR 0
- DRMA 1
- Target Price
- ALLR N/A
- DRMA $3.00
- AVG Volume (30 Days)
- ALLR 660.5K
- DRMA 108.7K
- Earning Date
- ALLR 05-09-2025
- DRMA 05-14-2025
- Dividend Yield
- ALLR N/A
- DRMA N/A
- EPS Growth
- ALLR N/A
- DRMA N/A
- EPS
- ALLR N/A
- DRMA N/A
- Revenue
- ALLR N/A
- DRMA N/A
- Revenue This Year
- ALLR N/A
- DRMA N/A
- Revenue Next Year
- ALLR N/A
- DRMA N/A
- P/E Ratio
- ALLR N/A
- DRMA N/A
- Revenue Growth
- ALLR N/A
- DRMA N/A
- 52 Week Low
- ALLR $0.61
- DRMA $0.69
- 52 Week High
- ALLR $20.44
- DRMA $5.00
- Technical
- Relative Strength Index (RSI)
- ALLR 36.97
- DRMA 36.40
- Support Level
- ALLR $1.02
- DRMA $0.77
- Resistance Level
- ALLR $1.06
- DRMA $0.85
- Average True Range (ATR)
- ALLR 0.08
- DRMA 0.04
- MACD
- ALLR -0.03
- DRMA -0.00
- Stochastic Oscillator
- ALLR 12.56
- DRMA 0.00
About ALLR Allarity Therapeutics Inc.
Allarity Therapeutics Inc is a clinical-stage, precision medicine company. The company is actively advancing a pipeline of in-licensed oncology therapeutics for patients with difficult-to-treat cancers. Its Drug Response Predictor (DRP) technology refines patient selection and improves clinical outcomes. Its pipeline product includes Dovitinib, Stenoparib, Ixempra, and other formulations.
About DRMA Dermata Therapeutics Inc.
Dermata Therapeutics Inc. is a clinical-stage medical dermatology company focused on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions and diseases. Its two product candidates, DMT310 and DMT410, incorporate its proprietary, multifaceted, Spongilla technology to topically treat a variety of dermatological conditions. Its Spongilla technology platform will enable to development and formulation of singular and combination products that can target topical delivery of chemical compounds into the dermis for maximum treatment effect for a variety of inflammatory skin diseases.